Pfizer Inc. has divulged cyclin-dependent kinase 2 (CDK2), 4 (CDK4) and 6 (CDK6) inhibitors reported to be useful for the treatment of cancer.

Glioblastoma multiforme is one of the most lethal cancers; when in grade IV, patients only have a median overall survival of 14.6 months.

Arvinas Operations Inc. has synthesized proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker.

Ildong Pharmaceutical Co. Ltd. has described GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

Exelixis Inc. has presented ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Scorpion Therapeutics Inc. has found compounds acting as cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.

Researchers from Vividion Therapeutics Inc. and partner Roche Holdings AG have published the discovery and preclinical characterization of the novel covalent allosteric inhibitor of WRN, VVD-133214 (RO-7589831).